亚胺培南西司他丁钠和美罗培南治疗重症感染的成本效果分析

Cost-efectiveness Analysis of Imipenem-cilastatin and Meropenem in the Treatment of Severe infectio

目的:评价亚胺培南西司他丁钠和美罗培南治疗重度感染的成本-效果。方法:将58例重症感染的患者,随机分为亚胺培南西司他丁钠组和美罗培南组进行治疗,采用药物经济学原理对两种治疗方案进行成本-效果分析。结果:亚胺培南西司他丁钠组和美罗培南组治疗重症感染的有效率分别为93.33%和85.71%(P>0.05);成本-效果比(C/E)分别为47.57和113.41。与亚胺培南西司他丁钠组相比,美罗培南组每增加一个单位效果需多花费692.91元。结论:亚胺培南西司他丁钠组的成本-效果比优于美罗培南组。亚胺培南西司他丁钠治疗重症感染有明显的药物经济学优势。

Objective:To evaluate cost-efectiveness of imipenem-cilastatin and meropenem injections in the treatmerit of severe infectio,in order to provide rational use of the drugs,and lower treatment cost.Methods:Principle of pharmacoeconomics was adopted to analyze cost-effectiveness of the two treatment schemes.Results:The effective rates of imipenem-cilastatin group and meropenem group in the treatment severe infectio were93.33%and85.71%(P >0.05)respectively.The cost-effectiveness ratio(C/E)were 47.57 and 113.41 respectively.The cost for every one unit increment of effectiveness for meropenem group was 693.91 yuan more than that of the imipenem-cilastatin group.Conclusion:Cost-efectiveness ratio of imipenem-cilastatin is superior to that of meropenem,and imipenem-cilastatin has marked pharmacoeconomics advantage over meropenem for severe infectio.